Short answer
CATALYST PHARMACEUTICALS, INC. (CPRX) filed an 8-K current report with the SEC on March 19, 2026 reporting Item 8.01 (Other Events). Bench trial on patent validity against Hetero USA delayed from March 23 to May 18, 2026.
CATALYST PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Bench trial on patent validity against Hetero USA delayed from March 23 to May 18, 2026
- Patents at issue protect FIRDAPSE and expire in 2032, 2034, and 2037
- Delay prolongs legal uncertainty regarding competitor’s market entry potential
- Outcome could materially affect revenue trajectory from FIRDAPSE exclusivity period
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CATALYST PHARMACEUTICALS, INC. 8-K filings
Get the next CPRX 8-K as it lands
Follow CPRX for push alerts, or ask the research agent what this filing means.